PRKAA1 and obesity due to melanocortin 4 receptor deficiency: Given its critical roles in controlling energy homeostasis, AMPK has attracted widespread interest as a potential therapeutic target for metabolic diseases, including obesity, type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD)6,10.